The abstract is read at the publisher; the summary is JClub's.
A reciprocally masked anti-CD47/IL-2 fusion protein (aCD47/IL-2c) achieves robust antitumor efficacy while improving systemic tolerability in human hCD47/hSIRPα1 transgenic mice.
- Why it matters: Potent immune modulators are constrained by systemic toxicity, and CD47 blockade or IL-2 activation alone can trigger hematologic or broad immune side effects.
- What they did: The team engineered aCD47/IL-2c with protease-cleavable linkers that sterically suppress each other in circulation, then used human and murine constructs to test masking, protease-dependent unmasking, tolerability, and efficacy in immunocompetent tumor models.
- The result: Antitumor activity required both CD47 blockade and IL-2 activity, correlated with inflammatory macrophage polarization and increased intratumoral effector CD8α T cells, and worked in an immune checkpoint-resistant melanoma model.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.